HLB바이오스텝 Stock: price and insider trades · South Korea

Every trade that managers of HLB바이오스텝 disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. Between 18 October 2025 and 18 October 2026, 14 insiders published 32 filings.

Open-market activity splits into 19 purchases totalling €1.3M and 12 sales; 12 insiders sit on the buying side and 10 insiders on the selling side. No amount is published for 29 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 5 board members, 4 senior executives and 1 major shareholder. One trade stands out by size: a purchase of €1.3M from Hlb, disclosed on 9 March 2026, or 5.0% of market capitalisation.

With 32 filings in twelve months, the company is more active than the median of 7 filings across the 2,628 companies we follow on the same exchange. Since 2021, the database holds 34 purchases and 38 sales by insiders of the company.

The clock since the last published purchase (21 July 2026) now reads 89 days. Filings reach the DART (FSS) feed a median of 7 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done.

For comparison within the same sector, see the insider buying recorded at MAIA Biotechnology, Inc. and Cooper Companies, Inc. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.